Head-to-head · Cost-Efficiency Index
CoreAge Rx vs Oak
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxOak
Dose-escalators. A flat per-dose price means titrating from 0.25mg to 2.4mg costs the same every month, so the twelve-month number you model on day one is the number you pay.
Visit OakThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 83. Best value on the board: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. Oak still earns a B — Dose-escalators. A flat per-dose price means titrating from 0.25mg to 2.4mg costs the same every month, so the twelve-month number you model on day one is the number you pay.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | Oak |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 83/100 |
| Semaglutide / mo | $149/mo | $119/mo (same price at every dose) |
| Tirzepatide / mo | $349/mo | $185/mo (same price at every dose) |
| Semaglutide / yr (modeled) | $1,788 | $1,428 |
| Tirzepatide / yr (modeled) | $4,188 | $2,220 |
| Coverage | All 50 states | 45 states (list not published) |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #1 | #18 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — cheaper teaser tiers exist (Direct GLP lists $65, Ondra $93 on semaglutide)
- No FDA-approved brand-name option (compounded only)
Oak
83/100Where the value is
- $119 semaglutide and $185 tirzepatide — both among the lowest published on this board, and published before the intake rather than after it
- "ONE PRICE · ALL DOSAGES · NO SUBSCRIPTIONS" — the price does not climb as your dose does, which is where most flat-looking programs quietly get expensive
- A non-injectable route as well as the two weekly injections: sublingual drops or tablets targeting the GLP-1 pathway
The tradeoffs
- It publishes three different prices for the same product: $119 in the homepage hero, $167 in the homepage comparison table and on /product, and $190 in the /weightloss comparison table
- The "$200 OFF — NEW PATIENT OFFER" and "SUMMER SALE — Save up to 60% vs. retail pricing" banners carry no terms, no code and no resulting price anywhere on the site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.